Yu Alice L, Paul Tobias, Schaumberger Markus, Welge-Lussen Ulrich
Department of Ophthalmology, Ludwig-Maximilians-University , Munich , Germany and.
Curr Eye Res. 2014 Dec;39(12):1240-6. doi: 10.3109/02713683.2014.906622. Epub 2014 Apr 21.
The goals of the present study were to evaluate the current use and accuracy of dose-taking prescription among patients with age-related macular degeneration (AMD) and to detect potential factors influencing the use or non-use of oral antioxidant supplements.
This is a cross-sectional questionnaire-based study of 65 patients with AMD of Age-Related Eye Disease Study (AREDS) category 3 (intermediate AMD) or category 4 (unilateral advanced AMD). Self-report data were obtained from a structural clinical interview in clinic. The patients were asked questions regarding their demographic, ophthalmologic and systemic data, their source of recommendation for antioxidant supplement use and/or their reasons for non-use. Afterwards, this information was correlated with the use or non-use of antioxidant supplements. Statistical analyses were conducted using a series of Mann-Whitney U-tests and Fisher's exact tests.
There were 55.4% (36 of 65) of the patients reporting antioxidant supplement use for AMD and 44.6% (29 of 65) with no supplement use. However, only 56.7% (17 of 30) took the recommended dose on label. There were significantly more female patients taking supplements than male patients (p = 0.010). A statistically significant correlation was also found between supplement use and the number of visits to an ophthalmologist per year (p = 0.037). The main reason for antioxidant supplement non-use was the missing awareness of the availability of antioxidant supplements.
Despite the recommendation of oral antioxidant supplements in the ARED Study for patients with AMD of category 3 or 4, only about half of these patients took the supplements in this study. Identifying the factors, which influenced the decision against supplement use, may help to better support patients in the prevention of severe vision loss caused by AMD.
本研究的目的是评估年龄相关性黄斑变性（AMD）患者目前服用剂量处方的情况和准确性，并检测影响口服抗氧化剂补充剂使用或不使用的潜在因素。
这是一项基于问卷调查的横断面研究，研究对象为65例年龄相关性眼病研究（AREDS）3类（中度AMD）或4类（单侧晚期AMD）的AMD患者。通过临床结构化访谈获取自我报告数据。询问患者有关其人口统计学、眼科和全身数据、抗氧化剂补充剂使用的推荐来源和/或不使用的原因。之后，将这些信息与抗氧化剂补充剂的使用或不使用情况相关联。使用一系列曼-惠特尼U检验和费舍尔精确检验进行统计分析。
55.4%（65例中的36例）的患者报告使用抗氧化剂补充剂治疗AMD，44.6%（65例中的29例）未使用补充剂。然而，只有56.7%（30例中的17例）服用了标签上推荐的剂量。服用补充剂的女性患者明显多于男性患者（p = 0.010）。还发现补充剂使用与每年看眼科医生的次数之间存在统计学显著相关性（p = 0.037）。不使用抗氧化剂补充剂的主要原因是对抗氧化剂补充剂可用性的认识不足。
尽管AREDS研究推荐3类或4类AMD患者口服抗氧化剂补充剂，但在本研究中只有约一半的患者服用了补充剂。识别影响不使用补充剂决策的因素，可能有助于更好地支持患者预防由AMD引起的严重视力丧失。
